- In March 2024, Synergia Medical announced the successful first-in-human implantation of its NAO.VNS vagus nerve stimulation device in Belgium, as part of the AURORA clinical trial. This trial reached its primary safety endpoints at 3 months with no serious adverse events reported. The company now plans to begin pivotal trials in Europe, the U.S., and Canada, positioning itself at the forefront of next-gen VNS therapies
- In April 2024, a landmark clinical trial published in Nature demonstrated that gamified, closed-loop vagus nerve stimulation significantly improves arm and hand function in stroke patients after just 12 weeks of therapy. This innovation combines VNS with physical therapy in a closed feedback loop, unlocking new treatment possibilities for post-stroke rehabilitation
- In February 2024, researchers published data showing that vagus nerve stimulation enhances quality of life in epilepsy patients—not only through seizure control but by improving mood, anxiety, and sleep. The study, which followed 113 adult patients from 2021–2024, adds new weight to VNS therapy’s role in holistic neurological care
- In January 2024, Pulsetto, a health tech company, launched its non-invasive VNS wearable in the U.K. retail market. Designed to reduce stress and anxiety through low-level stimulation of the vagus nerve, the GBP 500 gadget integrates with a mobile app and targets wellness-conscious consumers. Its entry reflects the growing trend of consumer-grade bioelectronic devices in Europe
- In August 2023, The Guardian reported the rapid progress of brain and nerve stimulation implants—including VNS systems—for treating conditions like epilepsy, arthritis, and even incontinence. The article highlighted key advancements across UK and EU clinical research hubs, emphasizing Europe’s accelerating role in next-generation neuromodulation innovation.
